Trials / Completed
CompletedNCT04223232
Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects
An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- MedDay Pharmaceuticals SA · Industry
- Sex
- Male
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This single-center, open-label, non randomized Phase I study is being conducted to investigate the pharmacokinetics, mass balance and metabolite profiling and identification after a single oral dose of 100mg of \[14C\]-MD1003 in 6 healthy males subjects. The radioactivity will be followed in the blood, urine and faeces to study MD1003 metabolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]-MD1003 | single oral dose of 100mg \[14C\]-MD1003 |
Timeline
- Start date
- 2019-12-10
- Primary completion
- 2020-01-22
- Completion
- 2020-01-22
- First posted
- 2020-01-10
- Last updated
- 2020-11-02
- Results posted
- 2020-11-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04223232. Inclusion in this directory is not an endorsement.